Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021

CAMBRIDGE, Mass. and BOULDER, Colo., July 27, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 10^th, from 10:55 -11:25am ET.

Access to the webcast of this event, as well as an archived recording, will be available under the 'Events' tab on the investor relations section of the Cogent Biosciences website at: https://investors.cogentbio.com/events.

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the newly formed Cogent Research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. Cogent Biosciences is based in Cambridge, MA and Boulder, Co. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cogent-biosciences-to-present-at-wedbush-pacgrow-virtual-healthcare-conference-2021-301341731.html

SOURCE Cogent Biosciences, Inc.

Amanda Sellers, [email protected], 301.332.5574